EGFR+ Lung Cancer | Clinical

Low-Level EGFR Variants in NSCLC Detectable by Liquid Biopsy Assays

November 20, 2020

Target capture next-generation sequencing, MassARRAY, and real-time quantitative polymerase chain reaction all effectively detected low frequency somatic epidermal growth factor receptor mutations in cell-free circulating tumor DNA from individuals with non–small cell lung cancer , according to a presentation at the AMP 2020 Annual Meeting and Expo.

Amivantamab Plus Lazertinib Combo Shows Good Results in EGFR+ NSCLC

November 10, 2020

Alexander Spira, MD, PhD, discusses the phase 1 CHRYSALIS trial of amivantamab plus lazertinib in 2 EGFR-mutant non–small cell lung cancer patient populations, which include patients with relapsed/refractory and those who are treatment-naive.

Pennell Considers Treatments in Front- and Later-Line Settings for EGFR+ NSCLC

November 08, 2020

In the treatment of EGFR-mutant non–small cell lung cancer, oncologists face multiple challenges with prescribing medications to patients. During a Targeted Oncology Case Based Peer Perspective event, Nathan Pennell, MD, PhD, discussed these challenges as well as potential treatment approaches with a group of peers.

Neratinib Shows Interim Efficacy in EGFR+ Non–Small Cell Lung Cancer

November 06, 2020

Treatment with neratinib achieved a high percentage of responses in patients with metastatic non–small cell lung cancer patients with EGFR exon 18 mutations who were dosed in a cohort during the interim analysis of the phase 2 SUMMIT basket trial.

FDA Approves First Companion Diagnostic Test for Expanded EGFR TKIs in NSCLC

October 30, 2020

The FDA has granted approval to the cobas EGFR Mutation Test v2 as a companion diagnostic for EGFR tyrosine kinase inhibitors as treatment of patients with EGFR-mutant non–small cell lung cancer, which is the first assay approved for this indication.

Adjuvant Osimertinib Induces Promising CNS DFS in Early Stage EGFR-Mutant NSCLC

October 27, 2020

In an interview with Targeted Oncology, Masahiro Tsuboi, MD, discussed the findings for the ADAURA study, which explored the role of osimertinib as treatment of patients with early-stage EGFR-mutant non-small cell lung cancer following a complete tumor resection.

Non-Chemotherapy Regimen Induces Encouraging Responses in Advanced EGFR-Mutant NSCLC

October 21, 2020

In an interview with Targeted Oncology, Alexander Spira, MD, PhD, discussed the findings from the clinical trial evaluating amivantamab in combination with lazertinib as treatment of patients with advanced EGFR-mutant non-small cell lung cancer.

ADAURA Study Demonstrates Promising Efficacy for Osimertinib in EGFR-Mutant NSCLC

October 19, 2020

Masahiro Tsuboi, MD, discusses the key takeaways from the findings for osimertinib in patients with early-stage EGFR-mutant non–small cell lung cancer following a complete tumor resection in the phase 3 ADAURA clinical trial.

Atezolizumab/Bevacizumab Plus Chemotherapy Sustains Survival Benefit After 20 Months in EGFR+ NSCLC

September 30, 2020

Atezolizumab in combination with bevacizumab, carboplatin, and paclitaxel demonstrated continued progression-free survival and overall survival benefit at 20 months of follow-up compared with chemotherapy alone in patients with chemotherapy-naïve metastatic nonsquamous non–small cell lung cancer who harbor an EGFR mutation, IMpower150 study results show.